Pune: The latest findings by the Indian Medical Research Council, which showed a lower level of neutralization antibodies against Delta variants in a small portion of the Covishield receiver may only notify the balance that supports third booster shots, experts say.
The ICMR study has shown a 4.5-fold reduction and 3.2-fold in neutralizing the antibody level against the Delta variant on those who were given one and two doses of covishield, respectively, compared to the previous SARS-COV-2 version which has D614G mutations (Detected early last year).
Dr.
Samiran Panda, Head of the Epidemiology Division of ICMR and infectious diseases, said, “This kind of observation has the potential to inform immunization programs, including possible needs for the third booster dose for vaccination against vaccination against vaccination against Covid-19.” For this study, serum samples were collected from healthy individuals who had received one or two covishield doses.
The sample was also collected from a patient restored Covid who had received one or two doses.
The five individual categories of whom the sample was taken were a breakthrough case – people who had contracted Covid after vaccination.
Dr.
Pragya Yadav from the National Institute of Virology, a member of the research team, said this study showed that serum participants were restored covid (given one or two doses) and a breakthrough case had a higher drop antibody titer compared to non-covid compared to non-covid Compared to non-covid participants who have received one or two Covishield shots.
“This shows that neutralizing antibodies on serum individuals who have contracted Covid, in a certain way, works like the first dose.
The full vaccination schedule after it produces a higher level of neutralization antibody.
Similarly, people who have received two covishield doses.
And contracted covid After that (breakthrough infection) has a higher level of neutralization antibody, “said Dr.
Panda.
In both cases, said Dr.
Panda, the immune system exposed three antigens, producing a larger immune response.
“The ICMR study can then help support discussions about whether the third dose of the Covishield Booster can be needed in the future for some cases.” Dr.
Yadav said, “Another important aspect of this study is the finding that a much less breeding of the severity and mortality.
Also, shows that even one dose is enough for long-term protection if they just recovered from Covid- 19.” He is Adding that the majority of individuals who are healthy vaccinated with one or two covishield doses do indeed show neutralized antibodies, while only a small portion that has no antibodies detected.
For this study, serum samples were collected four weeks after vaccination for all participant categories, except the breakthrough case.
In the last case (tested through RT-PCR), the sample was collected two weeks after completing the schedule of two doses.